Related Experiment Video
Updated: Mar 2, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
Published on: November 23, 2019
The Multi-Faceted Landscape of TEAD Inhibition: a 2017-2025 Patent and Literature Review
Violet Yijang Chen1, Jianfei Wan2, Xiao Ding2
1FLM4, ATMD-4, TSMC, Global R&D Center (F12P8), 168, Kehuan Rd., Hsinchu Science Park, Hsinchu 308-001, Taiwan; Insilico Medicine Taiwan Ltd., Suite 1303, No 333, Section 1, Keelung Rd, Xinyi Dist, Taipei, Taiwan.
Abstract:
TEAD (Transcriptional Enhanced Associated Domain) is a family of transcription factors whose involvement in the Hippo pathway plays a crucial role in cellular homeostasis and preventing tumorigenesis. Aberrant YAP/TAZ-TEAD activation is a key driver of various cancers, making it an attractive and therapeutically relevant target. Current challenges include nephrotoxicity as a potential on-target effect and acquired resistance, issues which are prompting the design of intermittent dosing schedules and the use of combination therapies. This review aims to provide a comprehensive overview of the current literature and patent landscape of TEAD inhibition, critically examining their mechanisms of action, preclinical and clinical efficacy, and therapeutic benefits. Covalent, non-covalent TEAD palmitate pocket binders, PPIDs and PROTACs are reviewed in part I, while part II will focus on their applications in mono- and combination therapies. The global patent database WIPO (World Intellectual Property Organization) as well as the chemical database SciFinder© were queried using the keywords "TEAD inhibitor", manually classified into PPID and non-PPID drugs and further subdivided into covalent and non-covalent inhibitors, resulting in 123 patents from March 2017 to December 2024 (excluding peptidomimetics and biologics).
More Related Videos
09:39A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Therapeutic Drug Monitoring: Affecting Factors
Clinical Trials: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Enzyme Inhibition